Ophthalmic Pharmaceutical Manufacturing

Sterling offers pharmaceutical services to the ophthalmic market. At Sterling, we have successfully guided a multitude of ophthalmic applications through federal regulations to bring into the commercial market.

Because drug companies understand that the ophthalmic market resides within a highly regulated and competitive market, Sterling has long been entrusted to oversee drug market introduction through these hurdles in a cost-efficient manner.

Our formulation and manufacturing services are all conducted within a sterile environment in our centralized facility located in the United States. In addition to an array of diagnostic solutions, our staff specializes in handling a variety of dosage forms for ophthalmic drugs, including antibiotic and lubricant ointments.

Sterling also specializes in performing full deformulation services, allowing for a Biowaiver (exemption) when filing with the FDA, when there is a proper Q1/Q2 match.

Our DEA (C2-C5) and FDA certified facilities have the capacity to handle new drug entities, technology transfers, and scale-ups in one-centralized location from concept to commercialization. Our continuous commitment to confidentiality and timeliness has allowed us to build not only a commercial partnership, but a relationship with our clients.